Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Sep 28;206(10):2111–2119. doi: 10.1084/jem.20090153

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 Lu et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 2. — IL-7, and not TSLP, has an additive effect on naive CD4⁺ T cell proliferation triggered by anti-CD3 and anti-CD28 mAbs. CFSE-labeled purified naive CD4⁺ T cells were cultured for 7 d in the presence of anti-CD28 and anti-CD3 mAbs alone or with either IL-7 or TSLP. The doses of anti-CD28, anti-CD3, IL-7, and TSLP are indicated. T cell proliferation was measured by FACS analysis on day 4 and by cell count on day 7 of culture. For the FACS results, numbers in each square state the percentage of proliferated T cells. For the cell count, data points represent the total number of expanded T cells of a donor, each represented by a different symbol. (A and B) The effect of increasing doses of anti-CD3 mAb on naive CD4⁺ T cell proliferation is shown. Data represent one of three independent experiments (A) and three donors (B). (C and D) The effect of increasing doses of IL-7 on naive CD4⁺ T cell proliferation in the presence of anti-CD28 and the suboptimal dose of anti-CD3 mAbs is shown. Data represent one of five independent experiments (C) and five donors (D). (E and F) The effect of increasing doses of TSLP on naive CD4⁺ T cell proliferation in the presence of anti-CD28 mAb and either the suboptimal or optimal dose of anti-CD3 mAb is shown. Data represent one of five independent experiments (E) and five donors (F).